학술논문
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial
Document Type
Article
Author
Laffel, Lori M; Danne, Thomas; Klingensmith, Georgeanna J; Tamborlane, William V; Willi, Steven; Zeitler, Philip; Neubacher, Dietmar; Marquard, Jan; Bardymova, Tatiana; Barrientos Perez, Margarita; Bethin, Kathleen; Bjornstad, Petter; Bondar, Irina; Chen, Mimi; Choi, Jin-Ho; Clements, Mark A; Colomar, Javier Ricardo; Daniels, Mark; Deerochanawong, Chaicharn; Desai, Vivek S; Desmangles, Jean-Claude G; Dillon, Robert G; Dixit, Naznin M; Du, Hongwei; Edelen, Rachel; Espinoza Peralta, Diego; Felipe Gacioppo, María Verónica; Ferraz, Tania Maria Bulcão Lousada; Galkina, Galina; Gallagher, Mary Patricia; George, Minu; Gonzalez, Edgar; Gottschalk, Michael Everett; Guido, Giancarlo; Hassan, Amir Ali; Hershkovitz, Eli; Huerta-Saenz, Lina P; Hwang, Jin Soon; Ibarra Gomez, Jaime Orlando; Irizarry Gonzalez, Lydia; Jain, Nina; Jelley, David H; Kim, Ho-Seong; Kovalenko, Tatiana; Laffel, Lori Michelle B; Leichter, Steven B; Liberatore Jr, Raphael Del Roio; Lynch, Jane; Mahmud, Farid Hussain; Malievskiy, Oleg Arturovich; Muir, Andrew; Nelson, Bryce A; Nevarez Ruiz, Luis Alejandro; Olson, Micah L; Pelayo Orozco, Emilia Susana; Peterkova, Valentina; Ramírez Mendoza, Fernando Ramón; Reddy, Konda Mohan; Rodriguez, Henry; Saenz, Javier Andres; Samoilova, Julia; Schwab, Karl-Otfried; Shah, Sejal H; Shehadeh, Naim; Shoemaker, Ashley H; Skorodok, Yulia; Sobolev, Aleksandr; Solís, Silvana Ernestina; Srinivasan, Shylaja; Tamborlane, William V; Tsalikian, Eva; Valeeva, Farida; Vance, Carl D; Velasquez-Mieyer, Pedro A; Violante Ortiz, Rafael Margarito; Votyakova, Olga; Wei, Haiyan; Weinstock, Ruth S; Wheeler, Mark D; Wicklow, Brandy Alexandra; Willi, Steven M; Wintergerst, Kupper A; Wolf, Risa M; Wood, Jamie Ruth; Yaliwal, Chandan; Yupanqui Lozno, Hernán
Source
The Lancet Diabetes & Endocrinology; March 2023, Vol. 11 Issue: 3 p169-181, 13p
Subject
Language
ISSN
22138587; 22138595
Abstract
The incidence of type 2 diabetes in young people is increasing, but treatments remain limited. We aimed to assess the efficacy and safety of an empagliflozin dosing regimen versus placebo and linagliptin versus placebo on glycaemic control in young people with type 2 diabetes.